Summary
255.18
0.79
(0.31%)
07/17/2026
AbbVie Inc. (ABBV)Key Facts
Performance
Historical returns1D
0.31%
1W
3.27%
1M
15.16%
3M
22.59%
6M
20.51%
1Y
37.62%
5Y
160.09%
Snapshot
Key statisticsClose
255.18
Change
0.79
Change %
0.31%
Open
257.04
Day Range
255.18 – 260.88
Volume
4,541,220
Avg Vol (20d)
9,584,613
Rel Vol
0.47x
52W Range
179.08 - 259.79
vs 52W High
-1.77%
vs 52W Low
42.50%
Gap
-3.00
Market Cap
USD 383.43B
Beta
0.35
Dividend Yield
3.86%
Price Chart
Advanced chartCompareLast 730 data points are shown. To view all data, Upgrade to PRO plan!
New Highs
Historical highs| Period | New Highs | From Last |
|---|---|---|
| 5-Day | 2× | 0.00% |
| 1-Month | 7× | -1.56% |
| 3-Month | 15× | -1.56% |
| 6-Month | 18× | -1.56% |
| YTD | 10× | -1.56% |
| Period | New Highs | From Last |
|---|---|---|
| 52-Week | 25× | -1.56% |
| 2-Year | 41× | -1.56% |
| 3-Year | 79× | -1.56% |
| 5-Year | 112× | -1.56% |
| 10-Year | 192× | -1.56% |
Financial SnapshotFY 2025
Full financialsRevenue
USD 61.16B
+8.6% YoY
Net Income
USD 4.23B
-1.4% YoY
EPS
2.37
-1.3% YoY
Gross Margin
70.2%
Operating Margin
32.8%
Net Margin
6.9%
EBITDA
USD 17.63B
Free Cash Flow
USD 17.82B
29.1% margin
ROE
-129.2%
ROA
3.2%
Debt / Equity
-21.12x
net debt USD 63.84B
Cash & Equiv.
USD 5.23B
Fundamental Ratings
MainB-
RecommendedSell
DCFBuy
ROEBuy
ROANeutral
Debt/EquityStrong Sell
P/EStrong Sell
P/BStrong Sell
Latest Earnings
- ABBV reported last earnings on 2026-04-29.
- EPS of $2.65 vs $2.59 estimated — surprise $0.06.
- Revenue of $15,002M vs $14,717M estimated — surprise $285M.
News
All newsAllergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE), for use in Europe: the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients
Boey® is the first and only rapid-onset and short-duration botulinum neurotoxin serotype E approved in Europe that adult patients can try for the temporary improvement of glabellar lines¹ Results may be seen as early as eight hours after treatment and typically wear off within approximately two...
Will AbbVie's Neuroscience Franchise Deliver Another Strong Quarter?
ABBV's neuroscience business is expected to post solid Q2 growth, with key brands and Vyalev in focus ahead of earnings on July 31.
Should You Buy, Sell or Hold ABBV Stock After Its 9% YTD Rise?
AbbVie ABBV stock has risen 8.9% so far this year as investor confidence strengthened in the company's post-Humira growth strategy. Despite Humira's U.S. patent expiry in 2023, AbbVie has successfully replaced much of the blockbuster's lost revenues with strong growth from Skyrizi and Rinvoq,...
AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It
AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
AbbVie vs Baxter: One Golden Cross Is Real, One Is a Trap
Both AbbVie (NYSE:ABBV | ABBV Price Prediction) and Baxter International (NYSE:BAX) flashed the same technical signal this month: a golden cross, where the 50-day moving average pushed above the 200-day.
Is AbbVie (ABBV) a Buy as Wall Street Analysts Look Optimistic?
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Which High-Yield ETF Is a Better Buy in 2026: Vanguard VYM vs iShares HDV?
VYM offers broader diversification with lower costs, while HDV is a more concentrated ETF with a heavy weightage on defensive stocks.
SkinMedica® Deepens Commitment to Regenerative Science with Continued Investment in Research and Development
SkinMedica ® launches Regenerative Science Advisory Board to shape future innovation Expands its state-of-the-art research and development (R&D) facility to support the next generation of science-led innovation Debuts flagship retail experiences designed to support practice and patients' needs...
Donald Trump's Drug-Pricing Deals Are Reshaping Big Pharma -- Here's What That Means for Pfizer, AbbVie, and Bristol Myers Squibb
Voluntary pricing deals reduce uncertainty for major drugmakers. Drug pricing pressure won't affect every pharmaceutical company equally.
Big Pharma's $300 Billion Patent Problem Fuels Biotech Deals
Big Pharma has a $300 billion problem, and biotech developers with promising drugs are becoming the fix. Major drugmakers are spending at a pace not seen since 2019 to replace medicines that will soon lose patent protection.
3 Dividend Stocks Built for Long-Term Buy-and-Hold Investors
You need to look beyond the tech sector to find great dividend stocks for the long term.
AbbVie Is Already a Dividend King. Here's Why the $10.9 Billion Apogee Deal Could Make It a Dynasty
AbbVie has a portfolio of attractive drugs, including branded products that are off-patent but still highly profitable. The company's acquisition of Apogee helps expand its drug pipeline.
AbbVie Inc (ABBV) Stock Down 0.7% but Still Overvalued -- GF Score: 76/100
On July 10, 2026, AbbVie Inc (ABBV) shares fell 0.7% to a current price of $248.08. This price is down from a 52-week high of $261.64 and remains significantly
Johnson & Johnson vs AbbVie: Two Paths to Pharma Dominance, One Winner
Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) and AbbVie (NYSE:ABBV) both posted Q1 2026 results that reshape how income investors should think about big pharma.
AbbVie (ABBV) Stock Drops Despite Market Gains: Important Facts to Note
In the closing of the recent trading day, AbbVie (ABBV) stood at $249.91, denoting a -1.12% move from the preceding trading day.
WST Completes SmartDose Sale to AbbVie to Focus on Core Growth
West Pharmaceutical completes the SmartDose 3.5mL sale to AbbVie, sharpening its focus on higher-growth on-body drug delivery technologies.
Vanguard Health Care vs. VanEck Pharmaceutical: How Do These ETFs Stack Up?
VHT offers broad diversification across 429 healthcare holdings, while PPH concentrates on 26 drugmakers for higher growth potential.
EU Approves Expanded Use of ABBV's Tepkinly in Follicular Lymphoma
AbbVie's EU approval expands Tepkinly into a first-of-its-kind bispecific lymphoma combination, backed by phase III data showing strong efficacy.
Buy these quality, low-stress stocks for the summer, says Jefferies
Markets have become more volatile as investors debate whether big tech companies are getting enough return on their AI spending. The S&P 500 momentum index has outperformed the wider market by more than 70% since 2024, close to levels seen during the 1990s dot-com era.
3 High-Yield Dividend Stocks to Buy and Hold Forever (Hint: AbbVie Makes the List)
AbbVie is hitting its stride now that it has transitioned past Humira's patent expiration. Medtronic is a steady dividend payer with some intriguing upside in robotics-assisted surgery.